Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ET89bio, Inc. logo

89bio, Inc. (ETNB)

NASDAQ Global Market · Currency in USD
$14.84 ▲ +0.00 (+0.00%)
At close: Oct 30, 4:00 PM ET. Market closed.

Summary

Previous Close
$14.84
Open
$14.84
Day's Range
$14.84 – $14.84
52 Week Range
$4.16 – $15.06
Volume
38,511,212
Avg. Volume
5,393,196
Market Cap
$2.20B
Beta (5Y Monthly)
1.26
PE Ratio (TTM)
--
EPS (TTM)
-$3.51
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$17.17

Profile: 89bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
93
CEO
Rohan Palekar
Website
89bio.com

Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia.

Earnings

DateEst.Actual
Nov 6, 2025-$0.50-$1.39Miss
Aug 7, 2025-$0.49-$0.71Miss
May 1, 2025-$0.50-$0.49Beat
Feb 27, 2025-$0.60-$1.02Miss
Nov 7, 2024-$0.64-$1.39Miss
Aug 5, 2024-$0.57-$0.48Beat

Analyst view

Consensus price target
$17.17 ▲ +15.7%
Range $12.00 – $25.00
Rating: Buy
Buy 60% · Hold 40% · Sell 0%

Get free alerts on ETNB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.